Document text
Principal Investigator: Florian Krammer
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $119,920
Funding agency: National Cancer Institute
PROJECT 1: ABSTRACT
Current information indicates that, in persons without cancer, natural infection with SARS-CoV-2 as well as
vaccination with COVID-19 vaccine candidates induce antibody responses to the spike protein of the virus
which should be protective against future infection. Lung cancer patients who become infected with SARS-
CoV-2 appear to develop severe COVID-19 with a high (35-40%) mortality rate indicating we urgently need to
plan for vaccine trials in this vulnerable population. Currently we have major knowledge gaps to fill in
preparation for such vaccine studies. These include: is there a higher incidence of SARS-CoV-2 in lung cancer
patients compared to the general population? Do lung cancer patients mount a comparable antibody response
in terms of quantity, quality, and longevity to people without lung cancer? Equally important are information in
lung cancer patients on the role of age, gender, smoking status, histology, and types of treatment for lung
cancer on both SARS-CoV-2 infection rate and generation of antibody responses. Through prospective
analyses of lung cancer cases (N= 1,000) and matched controls (N = 1,000) this Project “Characterization of
the Antibody Response to SARS-CoV-2 in Lung Cancer Patients” will provide answers to these important
questions through study of 4 specific aims and the use of our U54 Administrative, Clinical, and Data
Sciences Cores. Aim 1: Characterize the incident, magnitude and functionality of the antibody response to
SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 2: Compare the longevity of the
antibody response against SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 3:
Evaluate the impact of patient demographics and cancer-associated clinical factors on the antibody response
in lung cancer patients. And Aim 4: Characterize antibody responses to SARS-CoV-2 vaccination in lung
cancer patients versus non-lung cancer controls. The patient serology specimens will also be studied for viral
neutralizing functionality in collaboration with U54 Project 2. We have assembled a world-class team of lung
cancer clinical translational investigators, serology and virology experts, and patient advocates to address
these key issues. The results of this Project will have a significant impact on lung cancer patient management
during the COVID-19 pandemic, and even greater impact on designing optimal SARS-CoV-2 vaccination
regimens for lung cancer patients.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Address><Advocate><Age><Antibodies><Antibody Response><Assay><Binding><Bioassay><Biological Assay><COVID crisis><COVID epidemic><COVID incidence><COVID pandemic><COVID-19><COVID-19 antibody><COVID-19 case incidence><COVID-19 crisis><COVID-19 disease incidence><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 incidence><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 predisposition><COVID-19 public health crisis><COVID-19 susceptibility><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID-19 years><COVID19 infection><COVID19 virus><CV-19><Cancer Control><Cancer Control Science><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cells><Clinical><Clinical Sciences><Clinical Trials><CoV-2><CoV2><Collaborations><Complement><Complement Proteins><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Cricetinae><Data Science Core><Data Science Resource Core><Death Rate><Demographic Impact><Development><Epithelial Cells><Ethnic Origin><Ethnicity><Fc Receptor><Future><Gender><General Population><General Public><Generations><Glycoproteins><Hamsters><Hamsters Mammals><Histology><Immune><Immune response><Immunes><Immunity><Immunological response><Incidence><Individual><Infection><Kinetics><Knowledge><Length of Life><Longevity><Lung><Lung Respiratory System><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Marketing><Mediating><Modeling><Molecular Interaction><Patients><Persons><Policies><Population><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Predisposition><Preparation><Pulmonary Cancer><Pulmonary malignant Neoplasm><Race><Races><Receptor Protein><Regimen><Research Specimen><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 incidence><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Smoking History><Smoking Status><Specimen><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Susceptibility><Testing><Vaccinated><Vaccination><Vaccines><Viral><Viral Activity><Viral Antigens><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Physiology><Viral Proteins><Virus><Vulnerable Populations><Work><Wuhan coronavirus><ages><anti-cancer therapy><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody receptor><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><block viral entry><cancer therapy><cancer-directed therapy><clinical translation><clinically translatable><co-morbid><co-morbidity><comorbidity><comparative><complementation><corona virus><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><demographics><design><designing><developmental><hCoV19><host response><immune system response><immunoresponse><incidence rates of SARS-CoV-2 infection><incident cases of SARS-CoV-2><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><information gathering><inhibit viral entry><insight><inter-individual variability><inter-individual variation><interindividual variability><interindividual variation><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lung cancer><lung cancer cell><malignancy><mortality rate><mortality ratio><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neoplasm/cancer><neutralizing antibody><pack/year><patient response><patient specific response><power analysis><predisposed to Coronavirus disease 2019><preparations><prospective><protective efficacy><pulmonary><racial><racial background><racial origin><rate of infection><receptor><response><responsive patient><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><seropositive><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><statistical analysis><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><trait><translational investigator><translational researcher><translational scientist><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine response><vaccine responsiveness><vaccine study><vaccine trial><vaccine-induced response><vaccines preventing COVID><vaccines to prevent COVID><viral entry blocker><viral entry inhibitor><virology><virus antigen><virus protein><vulnerable group><vulnerable individual><vulnerable people><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2>